U.S., Aug. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07118319) titled 'The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis' on July 24.
Brief Summary: A Phase I Study to Assess the Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects with Amyotrophic Lateral Sclerosis
Study Start Date: Aug. 04
Study Type: INTERVENTIONAL
Condition:
Amyotrophic Lateral Sclerosis (ALS)
Intervention:
DRUG: Human Allogeneic Induced Pluripotent Stem Cells (iPSCs) -Derived Motor Neuron Progenitor Cells (XS228CN)
Injection, once, 6 months
DRUG: Human Allogeneic Induced ...